Christopher M Counter

12PUBLICATIONS
62CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Cancer geneticsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 14, 2026
CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

|May 28, 2026
Fusion-positive rhabdomyosarcoma oncofusions share a common interactome.

|Jan 20, 2026
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Rachel A Burge, Ozgun Le Roux, Olesja Popow

|Mar 06, 2025
The essential clathrin adapter protein complex-2 is tumor suppressive specifically in vivo.

Seth P Zimmerman, Lili B DeGraw, Christopher M Counter

|Mar 28, 2024
p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.

Özgün Le Roux, Jeffery I Everitt, Christopher M Counter

|Sep 07, 2022
Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.

Özgün Le Roux, Nicole L K Pershing, Erin Kaltenbrun

Pageof 2

Frequent Collaborators

3 joint publications

Özgün Le Roux

2 joint publications

Jack F Shern

2 joint publications

Kris C Wood

1 joint publications

M J A Groot Koerkamp